Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADVANCE: Efgartigimod IV in Adult Chronic Primary Immune Thrombocytopenia
jRCT2011220037Phase 3Completed
- Sponsor
- argenx
- Start
- Jun 2020
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial in immune thrombocytopenia (ITP) comparing Efgartigimod 10 mg/kg IV with Placebo IV (2 arms). Primary endpoint: Sustained platelet count response in chronic primary ITP. Started Jun 2020; status: completed.
02
Drugs
efgartigimod alfa
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on jRCT2011220037.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2011220037.